华润双鹤湘中药业（湖南）有限公司

Chinese pharmaceutical manufacturer in Shaoyang, Hunan, formerly Hunan Xiangzhong Pharmaceutical, which joined China Resources Double-Crane Pharmaceutical in August 2018 and is now a controlled subsidiary of that listed company. An integrated producer of active pharmaceutical ingredients and finished Chinese and Western medicines, it is a well-known Chinese base for antiepileptic drugs and psychiatric medicines, and in 2024 its parent committed a further 480 million yuan to build an API production base there in two phases over five years.